Full-Time

Utilities Systems Operator

Facilities and Engineering

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

CA$60.6k - CA$75.7kAnnually

+ Equity + Annual Bonus + RRSP Contribution

Mid, Senior

Vancouver, BC, Canada

Category
Manufacturing Engineering
Mechanical Engineering
Required Skills
Risk Management

You match the following AbCellera Biologics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 4 - 6 years experience in a manufacturing plant operation (steam plant, production, maintenance, quality, safety, and environmental compliance) or similar industry or a Bachelor's degree and a minimum of 3 years of relevant industry experience
  • Valid Technical Safety BC Class V Power Engineering certificate or higher
  • Knowledge and/or experience on base utilities equipment such as Boiler, Chiller, AHU, and Gases
  • Strong mechanical aptitude, electrical knowledge and ability to perform/supervise routine maintenance and repair tasks
  • Strong operational acumen with experience in risk management, and ability to prioritize science and engineering approaches to prevent process downtime
Responsibilities
  • Providing technical support operating our boilers and process vessels in compliance with the Technical Safety BC
  • Supporting the day-to-day safe and reliable monitoring and operation of all utilities equipment/systems (e.g. boilers, chillers, air handling units, water for injection, compressed air, clean gasses, etc.), including attendance to alarm in our building management system
  • Carrying out work order relating to routine maintenance and planned repair activities for utilities equipment through CMMS e-system
  • Performing shutdown and restart of utilities systems during major maintenance activities or unplanned power outage in accordance with internal safety and quality requirements
  • Providing technical support, troubleshooting, and problem-solving solutions for utilities systems interfacing with manufacturing process and quality control equipment
  • Providing recommendations for improvements on operations of utilities and base building equipment
  • May be asked to perform shift work based on company business needs and to ensure minimal downtime of facilities
Desired Qualifications
  • Hands-on experience in GMP clean utilities (e.g. Reverse Osmosis (RO) Water System, Water for Injection, Clean Compressed air, etc.)

AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and licensing its antibody candidates.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Biogen could solve the blood-brain barrier challenge in neuroscience.
  • Partnerships with Viking and ArrowMark may diversify revenue and enhance market presence.
  • Expanded collaboration with Eli Lilly could advance immunology, cardiovascular, and neuroscience programs.

What critics are saying

  • Increased competition in T-cell engagers may impact AbCellera's market share.
  • Failure in Biogen collaboration could harm reputation and financial outcomes.
  • Peter Thiel's resignation may lead to strategic shifts affecting investor confidence.

What makes AbCellera Biologics unique

  • AbCellera excels in antibody discovery with a proprietary, integrated technology platform.
  • The company partners with leading firms like AbbVie and Eli Lilly for drug development.
  • AbCellera's focus on multiomics and AI enhances its drug discovery efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

Securities.io
Jun 13th, 2024
Top 10 Biotech Big Data Companies

More Data For Better MedicineThe more we learn about biology, the more we realize all we do not know. It started with the genomic revolution and the first human genome sequenced in the early 2000s.Genomics has now been joined by other datasets like transcriptomics, proteomics, metabolomics, microbiome, etc. forming a new “multiomics” science. We discussed in further detail this evolution in “ Multiomics Are The Next Step In Biotechnology ”.These new tools have created a flood of data bringing detailed information about the inner activities of cells sometimes down to the atomic level. A key driver of this data growth has been the collapse of price of sequencing gene and other biological materials like proteins.This has created enthusiasm about “Big Data” potential in biotech, mimicking the concept of big data from other, more IT-driven fields.Already in 2018, the magazine Barron’s was asking “ Will Big Data Lead to Big Biotech Returns? ” and the industry started to ask “ Implementing Large-Scale Data Processing and Analysis for Bioprocessing ”Quite a few companies are well-positioned to benefit from the drive to create and analyze at-scale biological data.AI Merging With Big Data?A new development in the last few years has been the emergence of AI. While AI made its way into public consciousness mostly in 2023, with LLMs (Large Language Models) like ChatGPT, the biotech industry started to embrace AI many years before that.And it makes sense because data and AI have a somewhat symbiotic relationship:Training AI models requires a lot of data with high quality and annotations.AIs can help sort out massive datasets without direct human intervention and connect the dots where manual analysis would not be possible.The result is that today, a lot of the previously big data-focused companies in the biotech industry are also turning into AI companies.Contrary to some AI applications still looking for a business model (like image generation), drug discovery and medical research have a pretty straightforward path from AI model to monetization.Top 10 Big Data Biotech StocksIllumina is the leading genomics company, by far the largest and most established in the industry, with $1.2B in revenues, which grew 11% CAGR in the last 5 years.This also makes it the prime provider of genomic data to the entirety of the biotech industry.Like most genome sequencing companies, Illumina makes money when selling sequencers but mostly when selling the consumables used by the sequencers

Seeking Alpha
May 1st, 2024
AbCellera partners with PE firms to develop antibody drugs, company creation

AbCellera (NASDAQ:ABCL) has inked an agreement with Viking Global Investors and ArrowMark Partners to develop new antibody drug programs, with an initial focus on immunology.